An interventional study of memsorb in Anesthesia, sponsored by DMF Medical Incorporated. Completed at 2 sites in Canada. Per ClinicalTrials.gov, last updated 2026-02-23.
Sponsored by DMF Medical Incorporated · Not applicable, Interventional, and Other
The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.
DMF Medical has developed a next-generation CO2 filter in order to address the safety issues with current chemical CO2 absorbers in anesthesia.
memsorb uses patented advanced medical membrane technology to filter CO2 from anesthetic circuits rather than absorbing via a chemical reaction.
This game changing technology relies on a polymeric membrane core (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system, while maintaining the anesthetic vapor in the circuit.
memsorb is a cartridge similar in size and shape to current solutions that simply clicks in place.
DMF Medical Incorporated is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.
Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
Device: memsorb
memsorb is a CO2 filter replacing current chemical CO2 absorbers
End-tidal CO2 Concentration (%)
The mean concentration of carbon dioxide during the expiratory cycle, measured as a percentage (%), measured over the course of the surgical procedure.
Time frame: From the start to the end of the intra-operative period for each participant
Fraction of Anaesthetic Agent (%)
Inhaled and exhaled fraction of anaesthetic agent as collected from the anaesthetic patient record database. Mean % inhalational anesthetic was calculated per surgical procedure. Those means were used to calculate the overall mean
Time frame: From the start to the end of the intra-operative period for each participant
| Milestone | Control | Memsorb |
|---|---|---|
| Started | 111 | 175 |
| Completed | 111 | 175 |
| Not completed | 0 | 0 |
The mean concentration of carbon dioxide during the expiratory cycle, measured as a percentage (%), measured over the course of the surgical procedure.
| % end-tidal CO2 | Control | Memsorb |
|---|---|---|
| End-tidal CO2 Concentration (%) | 5.069 ± 0.8068 | 5.096 ± 0.5995 |
Inhaled and exhaled fraction of anaesthetic agent as collected from the anaesthetic patient record database. Mean % inhalational anesthetic was calculated per surgical procedure. Those means were used to calculate the overall mean
| percentage of fractional anesthetic agen | Control Group - inspSEVO | Control Group - ExpSEVO | Control Group - InspDes | Control Group - ExpDes | Memsorb Group - inspSEVO | Memsorb Group - ExpSEVO | Memsorb Group - inspDes | Memsorb Group - ExpDes |
|---|---|---|---|---|---|---|---|---|
| Fraction of Anaesthetic Agent (%) | 2.119 ± 0.7444 | 1.603 ± 0.6398 | 6.535 ± 1.582 | 5.505 ± 1.448 | 2.254 ± 0.6204 | 1.732 ± 0.5704 | 5.929 ± 1.539 | 5.158 ± 1.536 |
Collected over From the start to the end of the intra-operative period for each participant, an average of 1 hour.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control | 0/111 (0%) | 0/111 (0%) | 0/111 (0%) |
| Memsorb | 0/175 (0%) | 0/175 (0%) | 0/175 (0%) |
Surgical patients
| Age, Customized(participants) | Control | Memsorb | Total |
|---|---|---|---|
| ≥ 18 years | 111 | 175 | 286 |
| Sex: Female, Male(Participants) | Control | Memsorb | Total |
|---|---|---|---|
| Female | 55 | 87 | 142 |
| Male | 56 | 88 | 144 |
| Race and Ethnicity Not Collected(Participants) | Control | Memsorb | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
DMF Medical Incorporated